# A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets

Study · id `cardio:ct-nct05318326` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05318326](<https://clinicaltrials.gov/study/NCT05318326>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05318326

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

## Technical summary

Registry record NCT05318326. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT05318326, source copy `cardio:ctgov-nct05318326-2022-04-20`, retrieved 2026-10-26)
- Started: 2022-01-01 (actual) (ClinicalTrials.gov record NCT05318326, source copy `cardio:ctgov-nct05318326-2022-04-20`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05318326, source copy `cardio:ctgov-nct05318326-2022-04-20`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05318326, source copy `cardio:ctgov-nct05318326-2022-04-20`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05318326, source copy `cardio:ctgov-nct05318326-2022-04-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05318326-2022-04-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
- Condition: Type 2 Diabetes
- Intervention (Drug): placebo group
- Intervention (Drug): Yogliptin 400mg group
- Intervention (Drug): Yogliptin 200mg group
- Lead sponsor: Chengdu Easton Biopharmaceuticals Co,Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: b766faeb110939c3519f828f53e8d2400fd55860191a3b23a898458b6d5da028
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
